Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valeria Beretta

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Bio-Protocol|September 20, 2021
Melanoma Stem Cell Sphere Formation AssayAlessandra Tuccitto, Valeria Beretta, Francesca Rini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2008
Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responsesAnnaMaria De Filippo, Robert J Binder, Chiara Camisaschi, et al.
BMC Cancer|October 18, 2018
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patientsChiara Camisaschi, Salvatore Lorenzo Renne, Valeria Beretta, et al.
The Journal of Investigative Dermatology|January 21, 2014
Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3Chiara Camisaschi, Annamaria De Filippo, Valeria Beretta, et al.
Frontiers in Immunology|March 31, 2023
A longitudinal analysis of humoral, T cellular response and influencing factors in a cohort of healthcare workers: Implications for personalized SARS-CoV-2 vaccination strategiesEleonora Sabetta, Maddalena Noviello, Clara Sciorati, et al.
Journal of Immunology Research|December 5, 2018
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological TypesMarcella Tazzari, Silvia Brich, Alessandra Tuccitto, et al.
Stem Cells (Dayton, Ohio)|June 15, 2016
Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating CellsAlessandra Tuccitto, Marcella Tazzari, Valeria Beretta, et al.
Scientific Reports|February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockadeLicia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Bio-Protocol|September 20, 2021
Melanoma Stem Cell Sphere Formation AssayAlessandra Tuccitto, Valeria Beretta, Francesca Rini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2008
Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responsesAnnaMaria De Filippo, Robert J Binder, Chiara Camisaschi, et al.
BMC Cancer|October 18, 2018
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patientsChiara Camisaschi, Salvatore Lorenzo Renne, Valeria Beretta, et al.
The Journal of Investigative Dermatology|January 21, 2014
Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3Chiara Camisaschi, Annamaria De Filippo, Valeria Beretta, et al.
Frontiers in Immunology|March 31, 2023
A longitudinal analysis of humoral, T cellular response and influencing factors in a cohort of healthcare workers: Implications for personalized SARS-CoV-2 vaccination strategiesEleonora Sabetta, Maddalena Noviello, Clara Sciorati, et al.
Journal of Immunology Research|December 5, 2018
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological TypesMarcella Tazzari, Silvia Brich, Alessandra Tuccitto, et al.
Stem Cells (Dayton, Ohio)|June 15, 2016
Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating CellsAlessandra Tuccitto, Marcella Tazzari, Valeria Beretta, et al.
Scientific Reports|February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockadeLicia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.
Pageof 2